# Providence Investment Company Limited

> Providence Investment Company Limited is a VC fund in Germany backing Biotechnology and Biopharma. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Germany, United States
- Total investments: 14
- Last investment: Nov 2025
- Lead investor: 0%
- Last updated: Aug 2026

Providence Investment Company Limited is a VC fund in Germany focused on Biotechnology and Biopharma. Providence Investment Company

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $1.9M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 36% |
| Biopharma | 3 | 21% |
| Medical | 2 | 14% |
| Health Care | 2 | 14% |
| Therapeutics | 2 | 14% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 4 | 29% |
| Series B | 2 | 14% |
| Seed | 1 | 7% |
| Series A | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cambridge Photon Technology | Cambridge Photon Technology is a developer of organic photovoltaic devices used to enhance next-generation solar technology. Its devices engage in the deployment of off-grid solar power and use advanced nanotechnology to split each incoming blue and green photon into two infra-red photons that enable clients to deploy solar power throughlightweight devices whenever needed. | $1.2M |  | Nov 06, 2025 |  |
| evonetix | evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $24.1M | Series B | Feb 07, 2023 |  |
| evonetix | evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $30M | Series B | Mar 02, 2020 |  |
| DefiniGEN | DefiniGEN was founded in April 2012 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK.The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with morepredictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and in addition has in-licensed the Yamanka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc. | $1.9M | Series B | May 23, 2016 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. |  |  | Oct 19, 2015 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $5.6M |  | Jun 25, 2013 |  |
| Horizon Discovery | Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. | $8.8M |  | Jun 03, 2013 |  |
| Phico Therapeutics | Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to overcome antibacterial resistance. | $1.3M |  | Jan 01, 2009 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $4.3M |  | Oct 02, 2007 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $1.6M |  | Jul 18, 2006 |  |

10 of 14 investments shown.

## Co-investors
- [Cambridge Capital Group](https://shizune.co/investors/profile/cambridge-capital-group) — VC Fund, 4 deals together
- [Avlar BioVentures](https://shizune.co/investors/profile/avlar-bioventures) — VC Fund, 3 deals together
- [Molten Ventures](https://shizune.co/investors/profile/draper-esprit) — VC Fund, 3 deals together
- [Morningside Venture Partners](https://shizune.co/investors/profile/morningside-venture-partners-edb8) — VC Fund, 3 deals together
- [UK Innovation & Science Seed Fund](https://shizune.co/investors/profile/rainbow-seed-fund) — VC Fund, 3 deals together
- [Cambridge Consultants](https://shizune.co/investors/profile/cambridge-consultants) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors in United Kingdom](https://shizune.co/investors/biotech-investors-united-kingdom)
- [Biotech VC Funds in United Kingdom](https://shizune.co/investors/biotech-vc-funds-united-kingdom)
- [Medical Investors in United Kingdom](https://shizune.co/investors/medical-investors-united-kingdom)
- [Medical VC Funds in United Kingdom](https://shizune.co/investors/medical-vc-funds-united-kingdom)

## FAQ

### What does Providence Investment Company Limited invest in?

Providence Investment Company Limited invests primarily in Biotechnology, Biopharma and Medical startups, most often at Funding Round and Series B stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Providence Investment Company Limited's check size?

Providence Investment Company Limited typically joins rounds of $1.9M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Providence Investment Company Limited participates in.

### When did Providence Investment Company Limited last invest?

The most recent investment recorded for Providence Investment Company Limited closed in Nov 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co